Litigation
Boehringer Ingelheim Pharmaceuticals Inc. et al. v. Granules India Limited
dismissed1:24-cv-01091
Auto-generating section 1 of 4: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
Patents at issue (5)
Plaintiffs (3)
Defendants (1)
Summary
Hatch-Waxman ANDA-style action brought by Boehringer Ingelheim entities against Granules India Limited over JENTADUETO (linagliptin/metformin HCl). The suit asserted US 9,415,016 B2 plus US 10,022,379 B2, US 11,911,388 B2, US 10,973,827 B2, and US 9,155,705 B2. It was voluntarily dismissed without prejudice under Fed. R. Civ. P. 41(a)(1)(A)(i), with plaintiffs preserving the right to re-assert.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).